IFNA1 and ovarian cancer: The results showed that the drugs of bromodomain inhibitor PFI-1 (connectivity score = −0.6848, TAS = 0.3792), sorafenib (connectivity score = −0.6523, TAS = 0.3490), ATM kinase inhibitor CGK-773 (connectivity score = −0.6488, TAS = 0.4499), and mineralocorticoid antagonist spironolactone (connectivity score = −0.6349, TAS = 0.3050) with the signature strength larger than 200 and replicative correlation larger than 0.2 could be viewed as the candidate drugs targeting IFN signature in ovarian cancer (Supplementary Table 6).